Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy
Hepatitis B virus (HBV) reactivation (HBVr) can occur in patients receiving immunosuppressive drug therapies, causing significant morbidity and mortality. Although the guidelines for HBVr have been proposed by several academic societies, some providers do not follow them, resulting in HBVr and death...
Main Authors: | Akira Asai, Saho Hirai, Keisuke Yokohama, Tomohiro Nishikawa, Hiroki Nishikawa, Kazuhide Higuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/9/2446 |
Similar Items
-
Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective Studies
by: João Marcello de Araujo-Neto, et al.
Published: (2022-08-01) -
Can Hepatitis B Virus (HBV) Reactivation Result from a Mild COVID-19 Infection?
by: Ioannis Braimakis, et al.
Published: (2023-07-01) -
The efficacy of lamivudine in the treatment of reactivation of chronic hepatitis B virus infection in patients on immunosuppressive therapy
by: Delić Dragan, et al.
Published: (2011-01-01) -
High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus
by: Ming-Han Chen, et al.
Published: (2021-08-01) -
Prevention of Hepatitis B reactivation in the setting of immunosuppression
by: Venessa Pattullo
Published: (2016-06-01)